Midas Letter

CannTab Therapeutics Ltd (CSE:PILL) (OTCMKTS:CTABF) (FRA:TBF1) CFO Richard Goldstein visits Midas Letter Studios to discuss the recent stock surge and latest company developments. CannTab is a solid oral-dose tablet company, which started in the pharma business and then adapted its technologies to the cannabis space almost four years ago. The stock jumped as high as 98 percent and closed up 62.5 percent from the previous days closing price. The CFO explains “we had the little flurry of activity; we hope to have more trading and more interest behind the stock. We’re getting more eyeballs, and taking advantage of all our hard work.” CannTab recently graduated on the OTC to the QX listing making it easier for US investors to take ownership of the company. Mr. Goldstein believes tablets are truly the medical answer. The company’s bi-layered tablet, which are scheduled to be going into clinical trials soon, combine immediate release and extended release properties, using both CBD and THC. Additionally, the hard pill received an initial assessment from the Geneva-based International Preliminary Report on Patentability indicating the formulation is novel, non-obvious and useful.

Original article: CannTab Therapeutics Ltd (CNSX:PILL) Hard Pill Formulation is Patentable, Novel and Useful©2019 Midas Letter. All Rights Reserved.

Horizons ETFs Management (TSE:HMMJ) Senior Vice-President of ETF Strategy Mark Noble joins Midas Letter to discuss the downturn in the cannabis sector – which in his contrarian view provides investors with a entry opportunity into higher quality marijuana companies. Mr. Noble believes investors are looking solely at company earnings and profitability while overlooking company strategies for growth, especially direct investment into foreign markets looking to scale the companies global footprint. The Senior VP highlights Organigram and Aphria’s financials, as both companies generated a profit on Canadian revenues, but doesn’t believe other top cannabis companies should be punished in the markets while extending themselves outside of Canada for future growth capitalization. And there is where the potential opportunity may lie. As of the interview date, the HMMJ ETF is still up around 12 percent, although the whole sector has declined around 30 percent in the last quarter.

Original article: Horizons ETFs Management (TSE:HMMJ) Opportunity to Scale into Top Marijuana Companies©2019 Midas Letter. All Rights Reserved.

Galane Gold Ltd (TSX-V:GG) (OTCMKTS:GGGOF) (FRA:25G) Chairman Ravi Sood joins James to discuss some of the company highlights following their Q2 financials reported on August 15, 2019. Galane successfully produced 8,692 ounces of gold, and sold approximately 8,700 ounces at an average price of $1,305 per ounces. Their operating cash cost was $966 per ounce and positive cash flows from operating activities was $2,889,443.

The company’s Mupane gold mine, the only major gold producer of Botswana, is continuing to target production for the year of 32,000 ounces. The project has produced over 700,000 ounces of Gold in its history.

Galane gold’s Galaxy project situated covering 58.6 km² of the prolific South African Barberton Greenstone Belt is now in steady state production on the existing refurbished plant, and plan to reach full commercial production in the second half of 2020. According to the Chairman, all internal targets were exceeded for refurbishing the plant, mining from the Princeton mineralized body and producing concentrate. Galane Gold are targeting 2,300 ounces of payable gold to be produced in 2019 from Galaxy, but continue to target steady state annual production to average 25,000 ounces of gold at an operating cash cost per ounce of less than $800.

Mr. Sood also discusses the renewed interest in the gold industry as gold has stabilized at a price of level around $1,500.

Original article: Galane Gold Ltd (CVE:GG) Reports Financial Results for Q2 2019©2019 Midas Letter. All Rights Reserved.

Aurora Cannabis Inc (TSE:ACB) (OTCMKTS:ACBFF) (FRA:21P) CCO Cam Battley joins Midas Letter for a long-form interview diving into the latest developments inside one of the world’s largest and leading cannabis companies. The CCO states Aurora has “achieved a level of scale and discipline that sets us apart” [from the competition] which should see the company separate from the concerns in the cannabis market as a whole. Based on Aurora’s guidance, the company is anticipating between 90 and 95 million in cannabis revenues, which would put Aurora at the top of the cannabis pile in respect to revenue. James quizzes Mr. Battley with some ‘tough question’ such as when the company will be profitable, competing with low-cost, outdoor cannabis and extracts on the global stage and when Aurora’s relationship with Nelson Pelz is going to result in value for shareholders. Recent press releases are also discussed such as Aurora’s credit facility upsizing to USD$280 Million and their partnership with UFC® for clinical research of hemp-derived CBD products for MMA athletes.

Original article: 30 Minutes with Aurora Cannabis (TSE:ACB) (NYSE:ACB) CCO Cam Battley©2019 Midas Letter. All Rights Reserved.

Halo Labs Inc (NEO:HALO) (OTCMKTS:AGEEF) (FRA:A9KN) VP of Revenue Chad Kanner joins Midas Letter in Los Angeles, California to discuss the company’s product line, the concept behind them and the quality of Halo Labs’ concentrates. The VP of revenue outlines the demand for vaporizer products compared with dried flower saying the two have “very similar demand.” Halo Labs involvement with wholesale products, white label products, concentrates with medical industry pharmaceutical grades are also discussed. Within the interview, Mr. Kanner shows off several examples of Halo products available for the Californian concentrate market from the company’s Hush and Gilt product lines. Hush is a more of a budget-friendly but good quality concentrate option while Gilt is a high-end aspirational product line. 

The Hush product line includes both a line of strain-specific distillate cartridges and a line of strain-specific live resin pucks.

Gilt boasts two innovative product lines to appeal to the growing premium recreational consumer, DabTabs and a disposable Sauce Pen.

DabTabs are the brand’s flagship product offering and provide consumers with a convenient way to enjoy cannabis concentrates without the sticky residue.

The Sauce Pen features a disposable C-Cell battery and a unique formulation that preserves the taste and full spectrum experience that was previously only accessible to flower consumers.

Original article: Halo Labs Inc (NEO:HALO) Differentiated Vape Product Lines Generating Revenue©2019 Midas Letter. All Rights Reserved.

California Gold Mining Inc. (CSE:CGM) CEO Vishal Gupta joins James West again to discuss company developments. The company was poised for launching its hemp operations in California but has since pivoted into Illinois with the recent purchase of an 82 acre property. In remaining true to their word and committing to being cash flow positive before the end of this year, California Gold purchased the most fertile pieces of land that they’ve come across giving them an opportunity to take advantage of the outdoor cultivation season in Illinois for the calendar year of 2019.

Original article: California Gold Mining Inc (CNSX:CGM) Pivots Business Plan©2019 Midas Letter. All Rights Reserved.

ICC International Cannabis Corp (CNSX:WLRD.U) (FRA:8K51) (OTCMKTS:WLDCF) CEO David Shpilt joins Midas Letter to discuss the differentiating factors of the business within the competitive cannabis marketplace. ICC, through its subsidiaries, has operating assets and is developing platforms for cultivation, extraction, formulation and distribution across the globe and primarily in Europe. The main focus of the company will be the the medical European market as nations within the continent are regulated to medical standards only. The company is currently in the process of developing business units to become fully vertically integrated within that European market. Currently, ICC export dried flower out of Canada and import into Germany under compliance with EU GMP standards. Mr. Shpilt states the company will “be selling in Denmark, and then shortly in the UK.” Further to ICC’s European focus, the company will supply New Zealand’s NUBU Pharmaceuticals with a portfolio of full-spectrum pharmaceutical THC/CBD products. Watch the full interview to learn about all the company’s plans in the near-future as they look to become revenue-positive.

Original article: ICC International Cannabis Corp (CNSX:WLRD.U) Prep to be Player in European Cannabis Market©2019 Midas Letter. All Rights Reserved.

Khiron Life Sciences Corp (CVE:KHRN) (OTCMKTS:KHRNF) (FRA:4KH) President Chris Naprawa joins Midas Letter to discuss the recently released AltaCorp Capital research update. Senior Equity Research Analyst David Kideckel reiterated his “speculative buy” rating for the company with a price target of $6.00 – representing a return of over 200 per cent at the time of this interview.

“In our view, the market is completely discounting the value associated with Khiron’s entry into the medical cannabis product segment in other LATAM markets, which we believe is due to the regulatory uncertainty in those markets. However, we expect Khiron’s stock to revalue as the Company successfully enters into countries such as Mexico, Chile, and Brazil. There are several near-term catalysts that could drive the story, including revenues from the commercial launch of CBD in Colombia and new regulatory medical cannabis guidelines in Mexico, both of which are expected to happen in F2019,” – David Kideckel, AltaCorp Capital Senior Equity Research Analyst

Khiron’s president, though cannot speak to the forecasted numbers from three seperate analysts, believes people are starting to understand that the company is leading the way in the global cannabis business inside Latin America. Several different press releases released by the company in recent weeks support this notion. Mr. Naprawa comments on Khiron’s recently received conditional TSX-V approval for Latin American joint venture with Dixie Brands and U.S. distribution and sale of the company’s Kuida cosmeceutical line and Khiron’s move into the PGP business with SURA EPS. These pieces of news essentially allow Kuida products to expand globally with strong credibility and will allow Khiron to be able to cover cannabis with insurance in Colombia. Lastly, the Khiron Life Sciences president explains how the company’s demand in Colombia is greater than supply. The company are currently building the infrastructure to keep up with this “high” demand inside the country and also in Brazil, Uruguay plus other countries in South America.

Original article: Khiron Life Sciences Corp (CVE:KHRN) Achieves $6 Per Share Buy Rating From AltaCorp©2019 Midas Letter. All Rights Reserved.

48North Cannabis Corp (CVE:NRTH) (OTCMKTS:NCNNF) Co-CEO Alison Gordon joins Midas Letter to discuss completing the planting of its first outdoor cannabis crop at its Good:Farm facility. With over 3.7 million sq. ft. of cultivation space, Good:Farm is Canada’s largest outdoor organic cannabis cultivation facility. The cannabis culturist CEO rebuttals misconceptions of growing marijuana outdoors in Canada, stating the farms premium dried flower would pass Health Canada’s rigid inspections and that roughly 80 to 90 percent of the farm will be used for extraction and isolate purposes. The outdoor farm provides 48North with a huge opportunity within the cannabis market – in terms of a vastly greater cultivation space and lower costs. As 48North moves into harvesting its outdoor crop in a couple of weeks, the company have also made a strategic investment in Friendly Stranger – a cannabis accessories retailer in Ontario with operating retail experience of over 25 years. The investment marks the first retail investment made by 48North with the aim to dominate the retail cannabis market.

Be sure to check back in early September after Midas Letter visits 48North’s Good:Farm to see the massive outdoor grow in its entirety.

Original article: 48North Cannabis Corp (CVE:NRTH) Canada’s Largest Outdoor Organic Cannabis Operation©2019 Midas Letter. All Rights Reserved.

RavenQuest BioMed Inc (CNSX:RQB) (OTCMKTS:RVVQF) (FRA:1IT) CEO George Robinson joins Midas Letter to discuss the company’s recent approval from Health Canada to verify the proficiency and capability of the company’s orbital garden technology. The RavenQuest Orbital Garden allows for production of large quantities of cannabis in smaller areas by maximizing the productivity of grow space and lighting. After the evidence provided by Health Canada, the CEO is now ready to say RavenQuest is “best conditioned from a growing technology out of anyone, worldwide.” The novel growing technology is more efficient than traditional flat-table growing operations allowing for a decrease in the cost of power, nutrients and labour. Since the news, RavenQuest BioMed have been enjoying a surge of inquiries for possible technology uptake to global partners. Listen to the full interview to learn more about the company’s technological engineering feats and RavenQuest’s profitability expectations and future targets.

Original article: RavenQuest BioMed (CNSX:RQB) Best Conditioned Growing Technology Worldwide©2019 Midas Letter. All Rights Reserved.